Diabetic Peripheral Neuropathy Pipeline Insights

DelveInsight’s“Diabetic Peripheral Neuropathy Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Diabetic Peripheral Neuropathy pipeline landscapes. 

The report comprises Diabetic Peripheral Neuropathy pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Diabetic Peripheral Neuropathy therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Diabetic Peripheral Neuropathy pipeline products.     

Diabetic Peripheral Neuropathy Overview

Diabetic peripheral neuropathy (DPN) also known Distal symmetric polyneuropathy (DSPN) is defined as the  symptoms and/or signs of peripheral nerve dysfunction and nerve damage in diabetic patients after the exclusion of  other causes. It is a predominantly sensory neuropathy with autonomic nervous system involvement, although there  are often motor features with advancing disease.

It is a common prevalent complication in neurological damage of Type 1 and Type 2 diabetes. It is typically characterized by significant deficits in tactile sensitivity, vibration sense, lower-limb proprioception, and kinesthesia. Painful DPN has been shown to be associated with significant reductions in overall quality of life, increased levels of anxiety and depression, sleep impairment, and greater gait variability.

Some of the key takeaways from the Diabetic Peripheral Neuropathy Pipeline Report:

• Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Helixmith, WinSanTor, Regenacy Pharmaceutical, Aptinyx, Eli Lilly and Company, Lexicon Pharmaceuticals, etc., are developing therapies for the treatment of Diabetic Peripheral Neuropathy.
• Emerging therapies such as VM202, WST-057, Ricolinostat, NYX-2925, LY3016859, LX9211, are expected to have a significant impact on the  Diabetic Peripheral Neuropathy market in the coming years.

Get an overview of pipeline landscape @ Diabetic Peripheral Neuropathy Clinical Trials Analysis 

Diabetic Peripheral Neuropathy Pipeline Therapies along with Key Players:

1. VM202: Helixmith
2. WST-057: WinSanTor
3. Ricolinostat: Regenacy Pharmaceutical
4. NYX-2925: Aptinyx
5. LY3016859: Eli Lilly and Company
6. LX9211: Lexicon Pharmaceuticals

Scope of Diabetic Peripheral Neuropathy Pipeline Drug Insight    

• Coverage: Global 
• Major Players: Helixmith, WinSanTor, Regenacy Pharmaceutical, Aptinyx, Eli Lilly and Company, Lexicon Pharmaceuticals, and others.
• Pipeline Therapies: VM202, WST-057, Ricolinostat, NYX-2925, LY3016859, LX9211, and others.

Table of Contents

Related Reports:

Diabetic Peripheral Neuropathy Market

DelveInsight’s ‘Diabetic Peripheral Neuropathy-Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), 

Diabetic Peripheral Neuropathy Epidemiology

DelveInsight’s ‘Diabetic Peripheral Neuropathy Epidemiology Forecast to 2030′ report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/